KR20060120009A - 폴리에틸렌글리콜 개질된 지질 화합물 및 그의 용도 - Google Patents
폴리에틸렌글리콜 개질된 지질 화합물 및 그의 용도 Download PDFInfo
- Publication number
- KR20060120009A KR20060120009A KR1020067006599A KR20067006599A KR20060120009A KR 20060120009 A KR20060120009 A KR 20060120009A KR 1020067006599 A KR1020067006599 A KR 1020067006599A KR 20067006599 A KR20067006599 A KR 20067006599A KR 20060120009 A KR20060120009 A KR 20060120009A
- Authority
- KR
- South Korea
- Prior art keywords
- peg
- nucleic acid
- lipid
- particle
- splp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyethers (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
자살 유전자 생성물 | 덜 활성인 전구약물 | 활성화된 약물 |
헤르페스 심플렉스 바이러스 타입 1 티미딘 키나아제 (HSV-TK) | 간시클로버 (GCV), 아시클로버, 브로모비닐-데옥시우리딘, 또는 다른 기질 | 인산화된 dGTP 유사체 |
시토신 데아미나아제 (CD) | 5-플루오로시토신 | 5-플루오로우라실 |
크잔틴-구아닌-포스포리보실 트란스퍼라아제 (XGPRT) | 6-티오크잔틴 (6TX) | 6-티오구아노-시네모노포스페이트 |
퓨린 뉴클레오시드 포스포릴라아제 | MeP-dr | 6-메틸퓨린 |
시토크롬 P450 2B1 | 시클로포스파미드 | [세포독성 대사물] |
리나마라아제 (Linamarase) | 아미그달린 (amygdalin) | 시아니드 (cyanide) |
니트로리턱타아제 | CB 1954 | 니트로벤즈아미딘 |
베타-락타마아제 | PD | PD 머스타드(mustard) |
베타-글루쿠로니다아제 (glucuronidase) | adria (아드리아)-glu | 아드리아마이신 (adriamycin) |
카르복시펩티다아제 | MTX-알라닌 | MTX |
글루코오스 옥시다아제 | 글루코오스 | 과산화물 |
페니실린 아미다아제 | 아드리아-PA | 아드리아마이신 |
슈퍼옥시드 디스뮤타아제 (superoxide dismutase) | XRT | DNA 손상제 |
리보뉴클레아제 | RNA | 절단 생성물 |
군 | 마우스 수 | 세포 | 경로 | 처리 | 경로 | 투여 회수 | 최종 주사 후 시간 | 검정* |
A | 6 | 뉴로-2a | SC | PBS | IV | 1 | 48 시간 | 체중, 혈액 분석, 루시퍼라아제 활성 |
B | 6 | 뉴로-2a | SC | SPLP PEG-DSG | IV | 1 | 48 시간 | |
C | 6 | 뉴로-2a | SC | SPLP PEG-DSPE | IV | 1 | 48 시간 | |
D | 6 | 뉴로-2a | SC | SPLP PEG-세라미드C20 | IV | 1 | 48 시간 | |
E | 6 | 뉴로-2a | SC | SPLP PEG-A-DSA | IV | 1 | 48 시간 | |
F | 6 | 뉴로-2a | SC | SPLP PEG-C-DSA | IV | 1 | 48 시간 | |
G | 6 | 뉴로-2a | SC | SPLP PEG-S-DSA | IV | 1 | 48 시간 |
군 | 마우스 수 | 접종일 | 처리 | 주사일 | 수집일 |
A | 6 | 제 0 일 | PBS | 제 13 일 | 제 15 일 |
B | 6 | 제 0 일 | SPLP PEG-DSG | 제 13 일 | 제 15 일 |
C | 6 | 제 0 일 | SPLP PEG-DSPE | 제 13 일 | 제 15 일 |
D | 6 | 제 0 일 | SPLP PEG-세라미드C20 | 제 13 일 | 제 15 일 |
E | 6 | 제 0 일 | SPLP PEG-A-DSA | 제 13 일 | 제 15 일 |
F | 6 | 제 0 일 | SPLP PEG-C-DSA | 제 13 일 | 제 15 일 |
G | 6 | 제 0 일 | SPLP PEG-S-DSA | 제 13 일 | 제 15 일 |
군 | 마우스 수 | 종양 | 경로 | 처리 | 경로 | 투여 회수 | 시점 | 검정*** |
A | 4 | 뉴로-2a | SC | PBS | IV | 1 | 48 시간 | 체중, 혈액 분석, 루시퍼라아제 활성 |
B | 5 | 뉴로-2a | SC | SPLP PEG-DSG | IV | 1 | 48 시간 | |
C | 5 | 뉴로-2a | SC | SPLP PEG-A-DSA | IV | 1 | 48 시간 | |
D | 5 | 뉴로-2a | SC | SPLP PEG-A-DPA | IV | 1 | 48 시간 | |
E | 5 | 뉴로-2a | SC | SPLP PEG-A-DMA | IV | 1 | 48 시간 |
군 | 마우스 번호 | 접종일 | 처리 | 주사일 | 수집일 |
A | 4 | 제 0 일 | PBS | 제 12 일 | 제 14 일 |
B | 5 | 제 0 일 | SPLP PEG-DSG | 제 12 일 | 제 14 일 |
C | 5 | 제 0 일 | SPLP PEG-A-DSA | 제 12 일 | 제 14 일 |
D | 5 | 제 0 일 | SPLP PEG-A-DPA | 제 12 일 | 제 14 일 |
E | 5 | 제 0 일 | SPLP PEG-A-DMA | 제 12 일 | 제 14 일 |
군 | 마우스 수 | 세포 | 처리 | 경로 | 최종 주사 후 시점 | 검정* |
A | 4 | SC 뉴로-2a | 1 투여량 PBS | IV | 48 시간 | 루시퍼라아제 활성 |
B | 4 | SC 뉴로-2a | 1 투여량 L055-pSPLP PEG-DSG | IV | 48 시간 | |
C | 4 | SC 뉴로-2a | 1 투여량 L055-pSPLP PEG-DPG | IV | 48 시간 | |
D | 4 | SC 뉴로-2a | 1 투여량 L055-pSPLP PEG-DMG | IV | 48 시간 | |
E | 4 | SC 뉴로-2a | 1 투여량 L055-pSPLP PEG-A-DSA | IV | 48 시간 | |
F | 4 | SC 뉴로-2a | 1 투여량 L055-pSPLP PEG-A-DPA | IV | 48 시간 | |
G | 4 | SC 뉴로-2a | 1 투여량 L055-pSPLP PEG-A-DMA | IV | 48 시간 | |
H | 4 | SC 뉴로-2a | 1 투여량 L055-SPLP PEG-A-DSA | IV | 48 시간 | |
I | 4 | SC 뉴로-2a | 1 투여량 L055-SPLP PEG-A-DPA | IV | 48 시간 | |
J | 4 | SC 뉴로-2a | 1 투여량 L055-SPLP PEG-A-DMA | IV | 48 시간 | |
K | 4 | SC 뉴로-2a | 1 투여량 L055-SPLP PEG-A-DMA, 20 mg pDNA/Kg | IV | 48 시간 |
군 | 마우스 수 | 종양 SC | SPLP 처리 | 종결 |
A | 4 | 제 0 일 | 제 12 일 | 제 14 일 |
B | 4 | 제 0 일 | 제 12 일 | 제 14 일 |
C | 4 | 제 0 일 | 제 12 일 | 제 14 일 |
D | 4 | 제 0 일 | 제 12 일 | 제 14 일 |
E | 4 | 제 0 일 | 제 12 일 | 제 14 일 |
F | 4 | 제 0 일 | 제 12 일 | 제 14 일 |
G | 4 | 제 0 일 | 제 12 일 | 제 14 일 |
H | 4 | 제 0 일 | 제 12 일 | 제 14 일 |
I | 4 | 제 0 일 | 제 12 일 | 제 14 일 |
J | 4 | 제 0 일 | 제 12 일 | 제 14 일 |
군 | 마우스 수 | 종양 | 경로 | 처리 | 시점 | 경로 | 투여 회수 |
1 | 3 | 뉴로-2a | SQ | PBS/PBS | 48 h | IV | 1 |
24A | 4 | L055-SPLP/PBS 혼합물 | 24 h | ||||
24B | 4 | L055-SPLP/항-luc siRNA 리포좀 혼합물 | |||||
48A | 4 | L055-SPLP/PBS 혼합물 | 48 h | ||||
48B | 4 | L055-SPLP/항-luc siRNA 리포좀 혼합물 | |||||
72A | 4 | L055-SPLP/PBS 혼합물 | 72 h | ||||
72B | 4 | L055-SPLP/항-luc siRNA 리포좀 혼합물 |
군 | 마우스 수 | 접종일 | 경로 | IV 처리 | 시점 | 주사일 | 수집일 |
1 | 3 | 제 0 일 | SQ | PBS/PBS | 48 h | 제 13 일 | 제 15 일 |
24A | 4 | L055-SPLP/PBS 혼합물 | 24 h | 제 14 일 | |||
24B | 4 | L055-SPLP/항-luc siRNA 리포좀 혼합물 | 제 14 일 | ||||
48A | 4 | L055-SPLP/PBS 혼합물 | 48 h | 제 13 일 | |||
48B | 4 | L055-SPLP/항-luc siRNA 리포좀 혼합물 | 제 13 일 | ||||
72A | 4 | L055-SPLP/PBS 혼합물 | 72 h | 제 12 일 | |||
72B | 4 | L055-SPLP/항-luc siRNA 리포좀 혼합물 | 제 12 일 |
몰% (DSPC : Chol : PEG-C-DMA: DODMA) | |
A | 20: 50: 10: 15 |
B | 20: 61: 4: 15 |
C | 20: 63: 2: 15 |
군 | 처리 | 몰% (DSPC : Chol : PEG-C-DMA : 양이온성 지질) |
A | SPLP (15 몰% PEG-C-DMA) | 20: 50: 15: 15 |
B | SPLP (10 몰% PEG-C-DMA) | 20: 55: 10: 15 |
C | SPLP (5 몰% PEG-C-DMA) | 20: 60: 5: 15 |
샘플 설명 (PEG-지질 타입, 하전된 지질 타입) | 몰% (DSPC : Chol : PEG-지질: 하전된 지질) | |
A | SPLP (PEG-DSG, DODMA) | 20: 50: 15: 15 |
B | SPLP (PEG-DMG, DODMA) | 20 55: 10: 15 |
C | SPLP (PEG-C-DSA, DODMA) | 20: 60: 5: 15 |
D | SPLP (PEG-C-DMA, DODMA) | 20: 62.5: 2.5: 15 |
E | pSPLP (PEG-C-DSA, POPG) | 20: 55: 10: 15 |
F | pSPLP (PEG-C-DSA, DOP) | 20: 60: 5: 15 |
G | pSPLP (PEG-DSG, POPG) | 20: 62.5: 2.5: 15 |
몰% (DSPC : Chol : PEG-C-DMA: DODMA) | |
A | 20: 50: 15: 15 |
B | 20: 55: 10: 15 |
C | 20: 60: 5: 15 |
D | 20: 62.5: 2.5: 15 |
샘플 설명 | |
A | SPLP-PEG2000-C-DMA (CHOL: DSPC : DODMA: PEG2000-C-DMA 55: 20: 15: 10 몰%) |
B | SPLP-PEG750-C-DMA/DODMA (CHOL: DSPC : DODMA: PEG750-C-DMA 55: 20: 15: 10 몰%) |
C | SPLP-High PEG750-C-DMA (CHOL: DSPC : DODMA: PEG750-C-DMA 50: 20: 15: 15 몰%) |
D | SPLP-DODAC (CHOL: DSPC : DODMA: PEG2000-C-DMA: DODAC 45: 20: 15: 10: 10 몰%) 0.35 mg/ml |
군 | 처리 | 몰% (DSPC : Chol : PEG-C-DAA: DODMA) |
A | PBS | - |
B | 나출 siRNA | - |
C | SNALP (PEG-C-DMA) | 20: 40: 10: 30 |
D | SNALP (PEG-C-DMA) | 20: 46: 4: 30 |
E | SNALP (PEG-C-DMA) | 20: 48: 2: 30 |
F | SNALP (PEG-C-DMA) | 20: 49: 1: 30 |
Claims (62)
- 제 1 항에 있어서, 상기 알킬기가 라우릴 (C12), 미리스틸 (C14), 팔미틸 (C16), 스테아릴 (C18) 및 이코실 (C20)로 이루어진 군으로부터 선택된 것인 화합물.
- 제 1 항에 있어서, 상기 R1 및 R2가 동일한 것인 화합물.
- 제 3 항에 있어서, 상기 R1 및 R2가 둘 모두 미리스틸 (C14)인 화합물.
- 제 3 항에 있어서, 상기 R1 및 R2가 둘 모두 팔미틸 (C16)인 화합물.
- 제 3 항에 있어서, 상기 R1 및 R2가 둘 모두 스테아릴 (C18)인 화합물.
- 제 1 항에 있어서, 상기 알킬기가 포화된 것인 화합물.
- 제 1 항에 있어서, 상기 알킬기가 불포화된 것인 화합물.
- 제 1 항에 있어서, 상기 PEG가 약 550 달톤 내지 약 10,000 달톤 범위의 평균 분자량을 갖는 것인 화합물.
- 제 9 항에 있어서, 상기 PEG가 약 750 내지 약 5,000 달톤 범위의 평균 분자량을 갖는 것인 화합물.
- 제 9 항에 있어서, 상기 PEG가 약 1,000 내지 약 5,000 달톤 범위의 평균 분자량을 갖는 것인 화합물.
- 제 9 항에 있어서, 상기 PEG가 약 1,500 내지 약 3,000 달톤 범위의 평균 분자량을 갖는 것인 화합물.
- 제 9 항에 있어서, 상기 PEG가 약 2,000 달톤의 평균 분자량을 갖는 것인 화합물.
- 제 1 항에 있어서, 상기 비에스테르 함유 링커 잔기가 아미도 링커 잔기, 아미노 링커 잔기, 카르보닐 링커 잔기, 카르바메이트 링커 잔기, 우레아 링커 잔기, 에테르 링커 잔기, 디술피드 링커 잔기, 숙신아미딜 링커 잔기 및 이들의 조합물로 이루어진 군으로부터 선택되는 것인 화합물.
- 제 1 항에 있어서, 상기 비에스테르 함유 링커 잔기가 카르바메이트 링커 잔기인 화합물.
- 제 1 항에 있어서, 상기 비에스테르 함유 링커 잔기가 아미도 링커 잔기인 화합물.
- 제 1 항에 있어서, 상기 비에스테르 링커 잔기가 숙신아미딜 링커 잔기인 화합물.
- 제 18 항에 있어서, 생활성제를 추가로 포함하는 리포좀.
- 제 19 항에 있어서, 상기 생활성제가 항신생물제, 항생제, 면역조절제, 항염증제 및 중추신경계에 작용하는 약제로 이루어진 군으로부터 선택되는 것인 리포좀.
- 제 19 항에 있어서, 상기 생활성제가 단백질 또는 펩티드인 리포좀.
- 제 19 항에 있어서, 상기 생활성제가 핵산인 리포좀.
- 세포를 생활성제가 캡슐화되어 있는 제 18 항의 리포좀과 접촉시키는 것을 포함하여 생활성제를 세포에 전달하는 방법.
- 생활성제 캡슐화되어 있는 제 18 항의 리포좀을 환자에게 투여하는 것을 포함하여 생활성제를 환자에게 전달하는 방법.
- 제 25 항에 있어서, 상기 양이온성 지질이,N,N-디올레일-N,N-디메틸암모늄 클로라이드 (DODAC),N,N-디스테아릴-N,N-디메틸암모늄 브로마이드 (DDAB),N-(1-(2,3-디올레오일옥시)프로필)-N,N,N-트리메틸암모늄 클로라이드 (DOTAP),N-(l-(2,3-디올레일옥시)프로필)-N,N,N-트리메틸암모늄 클로라이드 (DOTMA), 및N,N-디메틸-2,3-디올레일옥시)프로필아민 (DODMA) 및 이들의 혼합물로 이루어진 군으로부터 선택되는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 비양이온성 지질이 디올레오일포스파티딜에탄올아민 (DOPE), 팔미토일올레오일포스파티딜콜린 (POPC), 에그 포스파티딜콜린 (EPC), 디스테아로일포스파티딜콜린 (DSPC), 팔미토일올레이올포스파티딜글리세롤 (POPG), 콜레스테롤 및 이들의 혼합물로 이루어진 군으로부터 선택되는 것인 핵산-지질 입 자.
- 제 25 항에 있어서, 상기 비양이온성 지질이 음이온성 지질인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 비양이온성 지질이 중성 지질인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 PEG-DAA 컨쥬게이트가 PEG-디라우릴옥시프로필 (C12), PEG-디미리스틸옥시프로필 (C14), PEG-디팔미틸옥시프로필 (C16), 및 PEG-디스테릴옥시프로필 (C18)로 이루어진 군으로부터 선택되는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 양이온성 지질이 상기 입자 중 존재하는 총 지질 중 약 2 % 내지 약 60 %를 차지하는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 양이온성 지질이 상기 입자 중 존재하는 총 지질 중 약 5 % 내지 약 45 %를 차지하는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 양이온성 지질이 상기 입자 중 존재하는 총 지질 중 약 5 % 내지 약 15 %를 차지하는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 양이온성 지질이 상기 입자 중 존재하는 총 지질 중 약 40 % 내지 약 50 %를 차지하는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 비양이온성 지질이 상기 입자 중 존재하는 총 지질 중 약 5 % 내지 약 90 %를 차지하는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 비양이온성 지질이 상기 입자 중 존재하는 총 지질 중 약 20 % 내지 약 85 %를 차지하는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 PEG-DAA 컨쥬게이트가 상기 입자 중 존재하는 총 지질 중 1 % 내지 약 20 %를 차지하는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 PEG-DAA 컨쥬게이트가 상기 입자 중 존재하는 총 지질 중 2 % 내지 약 15 %를 차지하는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 PEG-DAA 컨쥬게이트가 상기 입자 중 존재하는 총 지질 중 4 % 내지 약 10 %를 차지하는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 비양이온성 지질이 DSPC인 핵산-지질 입자.
- 제 25 항에 있어서, 콜레스테롤을 추가로 포함하는 핵산-지질 입자.
- 제 41 항에 있어서, 상기 콜레스테롤이 상기 입자 중 존재하는 총 지질 중 약 10 % 내지 약 60 %를 차지하는 것인 핵산-지질 입자.
- 제 41 항에 있어서, 상기 콜레스테롤이 상기 입자 중 존재하는 총 지질 중 약 20 % 내지 약 45 %를 차지하는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 PEG-DAA 컨쥬게이트가 PEG-디라우릴옥시프로필 (C12)인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 PEG-DAA 컨쥬게이트가 PEG-디미리스틸옥시프로필 (C14)인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 PEG-DAA 컨쥬게이트가 PEG-디팔미틸옥시프로필 (C16)인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 PEG-DAA 컨쥬게이트가 PEG-디스테릴옥시프로필 (C18)인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 핵산이 DNA인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 핵산이 플라스미드인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 핵산이 안티센스 올리고뉴클레오티드인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 핵산이 리보자임인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 핵산이 소형 간섭 RNA (siRNA)인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 핵산이 관심있는 치료 생성물을 엔코딩하는 것인 핵산-지질 입자.
- 제 53 항에 있어서, 상기 관심있는 치료 생성물이 펩티드 또는 단백질인 핵산-지질 입자.
- 제 53 항에 있어서, 상기 관심있는 치료 생성물이 소형 간섭 RNA (siRNA)인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 핵산-지질 입자를 37 ℃에서 20 분 동안 뉴클레아제에 노출시킨 후 상기 입자 중 핵산이 실질적으로 분해되지 않는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 상기 핵산-지질 입자를 37 ℃에서 30 분 동안 혈청 중에서 인큐베이션한 후 상기 입자 중 핵산이 실질적으로 분해되지 않는 것인 핵산-지질 입자.
- 제 25 항에 있어서, 핵산이 상기 핵산-지질 입자 중에 완전히 캡슐화된 것인 핵산-지질 입자.
- 제 25 항에 따른 핵산-지질 입자 및 약제학적으로 허용되는 담체를 포함하는 약제 조성물.
- 제 59 항에 있어서, PEG-DAA 컨쥬게이트가 PEG-디미리스틸옥시프로필 (C14)인 약제 조성물.
- 제 59 항에 있어서, PEG-DAA 컨쥬게이트가 PEG-디스테릴옥시프로필 (C18)인 약제 조성물.
- 세포를 양이온성 지질, 비양이온성 지질, PEG-DAA 컨쥬게이트 및 핵산을 포함하는 핵산-지질 입자와 접촉시키는 것을 포함하여 핵산을 세포에 도입시키는 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50323903P | 2003-09-15 | 2003-09-15 | |
US60/503,239 | 2003-09-15 | ||
PCT/CA2004/001677 WO2005026372A1 (en) | 2003-09-15 | 2004-09-15 | Polyethyleneglycol-modified lipid compounds and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060120009A true KR20060120009A (ko) | 2006-11-24 |
KR101164256B1 KR101164256B1 (ko) | 2012-07-10 |
Family
ID=34312435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067006599A Expired - Fee Related KR101164256B1 (ko) | 2003-09-15 | 2004-09-15 | 폴리에틸렌글리콜 개질된 지질 화합물 및 그의 용도 |
Country Status (10)
Country | Link |
---|---|
US (2) | US7803397B2 (ko) |
EP (1) | EP1664316B1 (ko) |
JP (1) | JP4842821B2 (ko) |
KR (1) | KR101164256B1 (ko) |
CN (1) | CN1882693B (ko) |
AU (1) | AU2004272646B2 (ko) |
CA (1) | CA2551022C (ko) |
IL (3) | IL174315A (ko) |
NZ (2) | NZ581166A (ko) |
WO (1) | WO2005026372A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150061946A (ko) * | 2013-11-28 | 2015-06-05 | 충남대학교산학협력단 | 효소 절단성 링커 또는 올리고 라이신을 포함하는 폴리에틸렌글리콜-리피드를 이용한 안정화된 플라스미드-지질 입자 |
Families Citing this family (375)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7514099B2 (en) | 2005-02-14 | 2009-04-07 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
US7935812B2 (en) | 2002-02-20 | 2011-05-03 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
EP2823809B1 (en) | 2002-06-28 | 2016-11-02 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
KR101168440B1 (ko) | 2003-07-16 | 2012-07-27 | 프로티바 바이오쎄라퓨틱스, 인코포레이티드 | 지질 캡슐화된 간섭 rna |
ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
AU2005251403B2 (en) | 2004-06-07 | 2011-09-01 | Arbutus Biopharma Corporation | Cationic lipids and methods of use |
CA2572439A1 (en) | 2004-07-02 | 2006-01-12 | Protiva Biotherapeutics, Inc. | Immunostimulatory sirna molecules and uses therefor |
WO2006020182A2 (en) * | 2004-07-16 | 2006-02-23 | Smart Medical Technologies, Llc | Centrifuge system |
GB0418172D0 (en) * | 2004-08-13 | 2004-09-15 | Ic Vec Ltd | Vector |
JP2008509205A (ja) * | 2004-08-13 | 2008-03-27 | アイシー・ベック・リミテッド | ポリマー修飾siRNAリポソームを含むベクター |
EP1828219A4 (en) * | 2004-11-17 | 2008-07-23 | Protiva Biotherapeutics Inc | ARNSI SILENCE OF APOLIPOPROTEIN B |
US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
WO2006074546A1 (en) * | 2005-01-13 | 2006-07-20 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
WO2006094203A1 (en) * | 2005-03-02 | 2006-09-08 | Northeastern University | Mitochondriotropic phospholipid vesicles |
EP1874793A4 (en) * | 2005-04-15 | 2008-12-24 | Univ Texas | DISTRIBUTION OF SIRNA BY NEUTRAL LIPID COMPOSITIONS |
US8304497B2 (en) * | 2005-05-02 | 2012-11-06 | The University Of Tokyo | Electrostatically bonded polymer vesicle |
AU2006274413B2 (en) | 2005-07-27 | 2013-01-10 | Arbutus Biopharma Corporation | Systems and methods for manufacturing liposomes |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
WO2007048046A2 (en) | 2005-10-20 | 2007-04-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of filovirus gene expression |
WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
US7915399B2 (en) * | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
EP3342415B1 (en) * | 2006-08-08 | 2022-01-26 | Rheinische Friedrich-Wilhelms-Universität Bonn | Structure and use of 5' phosphate oligonucleotides |
US20080171716A1 (en) * | 2006-08-16 | 2008-07-17 | Protiva Biotherapeutics, Inc. | Nucleic acid modulation of toll-like receptor-mediated immune stimulation |
JP5933163B2 (ja) * | 2006-10-03 | 2016-06-08 | テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation | 新規化合物 |
AU2014200910B2 (en) * | 2006-10-03 | 2017-02-09 | Arbutus Biopharma Corporation | Lipid containing formulations |
US20100035974A1 (en) * | 2006-10-04 | 2010-02-11 | Centre National De La Recherche Scientifique (Cnrs | Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof |
WO2008096690A1 (ja) * | 2007-02-05 | 2008-08-14 | Nippon Shinyaku Co., Ltd. | ポリエチレングリコール誘導体 |
EP2117304A4 (en) | 2007-02-07 | 2011-08-24 | Gradalis Inc | METHODS AND COMPOSITIONS FOR MODULATING SIALIC ACID PRODUCTION AND TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY |
EP2036577A1 (de) | 2007-09-14 | 2009-03-18 | mivenion GmbH | Diagnostische Stoffe für die optische bildgebende Untersuchung auf der Basis von nanopartikulären Formulierungen |
CN101918473A (zh) * | 2007-11-07 | 2010-12-15 | 犹他大学研究基金会 | 可还原聚(酰胺乙烯亚胺)的可切割修饰以增强核苷酸递送 |
CA2708153C (en) | 2007-12-04 | 2017-09-26 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
CA2710713C (en) | 2007-12-27 | 2017-09-19 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering rna |
US20110117125A1 (en) * | 2008-01-02 | 2011-05-19 | Tekmira Pharmaceuticals Corporation | Compositions and methods for the delivery of nucleic acids |
CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
AU2009236219B8 (en) | 2008-04-15 | 2015-06-25 | Arbutus Biopharma Corporation | Silencing of CSN5 gene expression using interfering RNA |
US8304565B2 (en) * | 2008-06-11 | 2012-11-06 | Nian Wu | PEG-lipid conjugates for liposomes and drug delivery |
WO2010008582A2 (en) | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
US20100099738A1 (en) * | 2008-09-10 | 2010-04-22 | Abbott Laboratories | Polyethylene glycol lipid conjugates and uses thereof |
WO2010033247A2 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
EP2743265B1 (en) | 2008-10-09 | 2017-03-15 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
CN102231952A (zh) * | 2008-11-17 | 2011-11-02 | 安龙制药公司 | 用于核酸运载系统的可释放阳离子脂质 |
TW201021852A (en) * | 2008-11-17 | 2010-06-16 | Enzon Pharmaceuticals Inc | Releasable fusogenic lipids for nucleic acids delivery systems |
WO2010074935A1 (en) * | 2008-12-22 | 2010-07-01 | Ge Healthcare Limited | Synthesis of obtaining modified polyethylene glycol intermediates |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
JP2012520686A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたシグナル伝達性転写因子6(STAT6)遺伝子発現のRNA干渉媒介性阻害 |
JP2012520684A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたBTBandCNCHomology1(塩基性ロイシンジッパー転写因子1)(Bach1)遺伝子発現のRNA干渉媒介性阻害 |
EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120016011A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
CN104922676B (zh) * | 2009-03-20 | 2019-03-12 | Clsn实验室股份有限公司 | 聚胺衍生物 |
US20120004282A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp, | RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20120022143A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA) |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
EP2411019A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US9080186B2 (en) | 2009-05-16 | 2015-07-14 | Agave Pharma, Incorporated | Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules |
KR20120039564A (ko) * | 2009-06-02 | 2012-04-25 | 니안 우 | 순수 peg-지질 컨쥬게이트 |
EP2449114B9 (en) | 2009-07-01 | 2017-04-19 | Protiva Biotherapeutics Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US8716464B2 (en) | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
DK2474306T3 (en) * | 2009-08-31 | 2017-02-06 | Nanocarrier Co Ltd | PARTICLE COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING SAME |
CA2775092A1 (en) | 2009-09-23 | 2011-03-31 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
CN102216773B (zh) * | 2009-10-07 | 2014-03-19 | 松下电器产业株式会社 | 人工脂质膜形成方法 |
WO2011046983A2 (en) | 2009-10-12 | 2011-04-21 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
EP2496700B1 (en) | 2009-11-04 | 2017-03-01 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
EP3403647A1 (en) | 2009-12-01 | 2018-11-21 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
CA3009891C (en) * | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
US20130034599A1 (en) * | 2010-01-19 | 2013-02-07 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
WO2011127255A1 (en) | 2010-04-08 | 2011-10-13 | Merck Sharp & Dohme Corp. | Preparation of lipid nanoparticles |
US10077232B2 (en) | 2010-05-12 | 2018-09-18 | Arbutus Biopharma Corporation | Cyclic cationic lipids and methods of use |
US20130123338A1 (en) | 2010-05-12 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
AU2011268146A1 (en) | 2010-06-17 | 2013-01-10 | Actogenix Nv | Compositions and methods for treating inflammatory conditions |
WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
US20130210663A1 (en) | 2010-08-04 | 2013-08-15 | Cizzle Biotechnology Limited | Methods and compounds for the diagnosis and treatment of cancer |
EP3372684B1 (en) | 2010-08-24 | 2020-10-07 | Sirna Therapeutics, Inc. | Single-stranded rnai agents containing an internal, non-nucleic acid spacer |
WO2012027467A1 (en) | 2010-08-26 | 2012-03-01 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP4066856B1 (en) | 2010-08-31 | 2022-12-07 | GlaxoSmithKline Biologicals SA | Pegylated liposomes for delivery of immunogen-encoding rna |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
DK2663548T3 (en) | 2011-01-11 | 2017-07-24 | Alnylam Pharmaceuticals Inc | PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY |
KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
DK2718269T3 (en) | 2011-06-08 | 2018-04-09 | Translate Bio Inc | SPLITLY LIPIDS |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
TR201802662T4 (tr) | 2011-07-06 | 2018-03-21 | Glaxosmithkline Biologicals Sa | Nükleik asitler içeren su içinde yağ emülsiyonları. |
SG10201605500TA (en) | 2011-07-06 | 2016-08-30 | Novartis Ag | Cationic oil-in-water emulsions |
US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
CN102973506B (zh) * | 2011-09-05 | 2015-06-03 | 中国科学院深圳先进技术研究院 | 阳离子脂质体及其制备方法 |
GB201116248D0 (en) * | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
JP6250543B2 (ja) | 2011-09-27 | 2017-12-20 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | ジ脂肪族置換peg化脂質 |
US9061063B2 (en) | 2011-12-07 | 2015-06-23 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
NZ700075A (en) | 2012-02-24 | 2016-05-27 | Protiva Biotherapeutics Inc | Trialkyl cationic lipids and methods of use thereof |
CA2868034C (en) | 2012-03-29 | 2021-07-27 | Shire Human Genetic Therapies, Inc. | Ionizable cationic lipids |
CA2868030C (en) | 2012-03-29 | 2021-05-25 | Shire Human Genetic Therapies, Inc. | Lipid-derived neutral nanoparticles |
CN104582691A (zh) * | 2012-05-23 | 2015-04-29 | 俄亥俄州立大学 | 脂膜白蛋白纳米颗粒组合物以及制备和使用其的方法 |
WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
JP6561378B2 (ja) | 2012-06-08 | 2019-08-21 | トランスレイト バイオ, インコーポレイテッド | 非肺標的細胞へのmRNAの経肺送達 |
ES2883590T3 (es) | 2012-12-12 | 2021-12-09 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas |
TR201901310T4 (tr) | 2013-03-14 | 2019-02-21 | Translate Bio Inc | Mesajcı RNA'nın saflaştırılması yöntemleri. |
SMT201800546T1 (it) | 2013-03-14 | 2019-01-11 | Translate Bio Inc | Composizioni di mrna di cftr e metodi e usi correlati |
AU2014239184B2 (en) | 2013-03-14 | 2018-11-08 | Translate Bio, Inc. | Methods and compositions for delivering mRNA coded antibodies |
US20140288149A1 (en) | 2013-03-15 | 2014-09-25 | Graham Lord | Mir-142 and antagonists thereof for treating disease |
EP2971013B1 (en) | 2013-03-15 | 2020-08-19 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
DK3388834T3 (da) | 2013-03-15 | 2020-05-04 | Translate Bio Inc | Synergistisk forbedring af levering af nukleinsyrer via blandede formuleringer |
CN113425857B (zh) | 2013-06-17 | 2025-05-16 | 布罗德研究所有限公司 | 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途 |
SG11201510327TA (en) | 2013-06-17 | 2016-01-28 | Broad Inst Inc | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
CN105793425B (zh) | 2013-06-17 | 2021-10-26 | 布罗德研究所有限公司 | 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用 |
EP3677567A1 (en) * | 2013-07-23 | 2020-07-08 | Arbutus Biopharma Corporation | Compositions and methods for delivering messenger rna |
MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
BR112016009077A2 (pt) | 2013-10-22 | 2017-09-19 | Shire Human Genetic Therapies | Formulações lipídicas para fornecimento de rna mensageiro |
JP6608815B2 (ja) | 2013-10-22 | 2019-11-20 | トランスレイト バイオ, インコーポレイテッド | アルギニノコハク酸合成酵素欠損症のmRNA治療 |
EP3060671B1 (en) | 2013-10-22 | 2021-12-29 | Translate Bio, Inc. | Cns delivery of mrna and uses thereof |
US10772974B2 (en) | 2013-11-18 | 2020-09-15 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for cardiac regeneration |
WO2015089473A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
EP3080257A1 (en) | 2013-12-12 | 2016-10-19 | The Broad Institute Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
CN105899658B (zh) | 2013-12-12 | 2020-02-18 | 布罗德研究所有限公司 | 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用 |
JP6793547B2 (ja) | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物 |
CN106061510B (zh) | 2013-12-12 | 2020-02-14 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
AU2014361826A1 (en) | 2013-12-12 | 2016-06-23 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using particle delivery components |
EP3110401A4 (en) | 2014-02-25 | 2017-10-25 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
US9833416B2 (en) * | 2014-04-04 | 2017-12-05 | Ohio State Innovation Foundation | Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same |
EA201691696A1 (ru) | 2014-04-25 | 2017-03-31 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
US10022455B2 (en) | 2014-05-30 | 2018-07-17 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
CA2952121A1 (en) | 2014-06-13 | 2015-12-17 | Childrens' Medical Center Corporation | Products and methods to isolate mitochondria |
KR102387898B1 (ko) | 2014-06-24 | 2022-04-15 | 샤이어 휴먼 지네틱 테라피즈 인크. | 핵산의 전달용 입체화학적으로 풍부한 조성물 |
JP6594421B2 (ja) | 2014-06-25 | 2019-10-23 | アクイタス セラピューティクス インコーポレイテッド | 核酸の送達のための新規脂質および脂質ナノ粒子製剤 |
BR112016030852A2 (pt) | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
EP3686279B1 (en) | 2014-08-17 | 2023-01-04 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
BR112017006679A2 (pt) | 2014-10-02 | 2017-12-26 | Protiva Biotherapeutics Inc | moléculas, composição, partícula, composição farmacêutica, métodos para silenciar a expressão de um gene, usos de uma partícula, métodos para melhorar um ou mais sintomas, métodos para tratar uma infecção, usos de uma composição, método para inibir a replicação do vírus da hepatite d |
ES2861597T3 (es) | 2014-12-05 | 2021-10-06 | Translate Bio Inc | Terapia de ARN mensajero para el tratamiento de enfermedad articular |
WO2016094872A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
WO2016100974A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
AU2015369725A1 (en) | 2014-12-24 | 2017-06-29 | Massachusetts Institute Of Technology | CRISPR having or associated with destabilization domains |
EP3270894B1 (en) | 2015-03-19 | 2021-02-24 | Translate Bio, Inc. | Mrna therapy for pompe disease |
WO2016197132A1 (en) | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics Inc. | Treating hepatitis b virus infection using crispr |
EP3436575A1 (en) | 2015-06-18 | 2019-02-06 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2016205764A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2016205745A2 (en) * | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
TWI813532B (zh) | 2015-06-18 | 2023-09-01 | 美商博得學院股份有限公司 | 降低脱靶效應的crispr酶突變 |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
AU2016285852B2 (en) | 2015-06-29 | 2020-12-17 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2017019891A2 (en) | 2015-07-29 | 2017-02-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis b virus gene expression |
WO2017031370A1 (en) | 2015-08-18 | 2017-02-23 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
BR112018003784A2 (pt) | 2015-08-24 | 2018-09-25 | Halo-Bio Rnai Therapeutics, Inc. | nanopartículas de polinucleotídeo para a modulação da expressão gênica e sua utilização |
US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
JP6997704B2 (ja) | 2015-10-14 | 2022-02-04 | トランスレイト バイオ, インコーポレイテッド | 生産性向上のためのrna関連酵素の修飾 |
US12234454B2 (en) | 2015-10-22 | 2025-02-25 | The Broad Institute, Inc. | Crispr enzymes and systems |
US11492670B2 (en) | 2015-10-27 | 2022-11-08 | The Broad Institute Inc. | Compositions and methods for targeting cancer-specific sequence variations |
EP3368689B1 (en) | 2015-10-28 | 2020-06-17 | The Broad Institute, Inc. | Composition for modulating immune responses by use of immune cell gene signature |
PT3368507T (pt) | 2015-10-28 | 2023-02-07 | Acuitas Therapeutics Inc | Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017095944A1 (en) | 2015-11-30 | 2017-06-08 | Flagship Pioneering, Inc. | Methods and compositions relating to chondrisomes from blood products |
WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
AU2017208013B2 (en) | 2016-01-15 | 2022-12-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic use of mitochondria and combined mitochondrial agents |
EP3825400B1 (en) | 2016-04-08 | 2024-12-25 | Translate Bio, Inc. | Multimeric coding nucleic acid and uses thereof |
US20210155911A1 (en) | 2016-04-19 | 2021-05-27 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
AU2017257274B2 (en) | 2016-04-19 | 2023-07-13 | Massachusetts Institute Of Technology | Novel CRISPR enzymes and systems |
US11286478B2 (en) | 2016-04-19 | 2022-03-29 | The Broad Institute, Inc. | Cpf1 complexes with reduced indel activity |
CA3027312A1 (en) | 2016-06-13 | 2017-12-21 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
JP7267013B2 (ja) | 2016-06-17 | 2023-05-01 | ザ・ブロード・インスティテュート・インコーポレイテッド | Vi型crisprオルソログ及び系 |
US20210222164A1 (en) | 2016-06-29 | 2021-07-22 | The Broad Institute, Inc. | Crispr-cas systems having destabilization domain |
CN109563511A (zh) | 2016-06-30 | 2019-04-02 | 阿布特斯生物制药公司 | 用于递送信使rna的组合物和方法 |
CN109715167A (zh) * | 2016-08-03 | 2019-05-03 | 神经孔疗法股份有限公司 | 脂质取代的氨基1,2-和1,3-二醇化合物作为tlr2二聚化的调节剂 |
WO2018035388A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
CN110312799A (zh) | 2016-08-17 | 2019-10-08 | 博德研究所 | 新型crispr酶和系统 |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
US20200016202A1 (en) | 2016-10-07 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2018075592A1 (en) | 2016-10-21 | 2018-04-26 | Merck Sharp & Dohme Corp. | Influenza hemagglutinin protein vaccines |
EP3532103A1 (en) | 2016-10-26 | 2019-09-04 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
EP3596207B1 (en) | 2017-03-15 | 2023-12-20 | The Broad Institute, Inc. | Novel cas13b orthologues crispr enzymes and systems |
WO2019012336A2 (en) | 2017-03-17 | 2019-01-17 | Newcastle University | ADENO-ASSOCIATED VIRAL VECTOR DELIVERY OF A MICRO-DYSTROPHIN FRAGMENT FOR TREATING MUSCLE DYSTROPHY |
BR112019021378A2 (pt) | 2017-04-12 | 2020-05-05 | Massachusetts Inst Technology | ortólogos de crispr tipo vi inovadores e sistemas |
WO2018191719A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipid delivery of therapeutic agents to adipose tissue |
WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
US12350368B2 (en) | 2017-04-14 | 2025-07-08 | The Broad Institute, Inc. | Delivery of large payloads |
CA3061612A1 (en) | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2018204777A2 (en) | 2017-05-05 | 2018-11-08 | The Broad Institute, Inc. | Methods for identification and modification of lncrna associated with target genotypes and phenotypes |
BR112019023323A2 (pt) | 2017-05-08 | 2020-07-21 | Flagship Pioneering Innovations V, Inc. | composições para facilitar a fusão de membrana e usos das mesmas |
AU2018268859B2 (en) | 2017-05-16 | 2024-07-25 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR |
EP3625342B1 (en) | 2017-05-18 | 2022-08-24 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
WO2018232017A1 (en) | 2017-06-13 | 2018-12-20 | Flagship Pioneering, Inc. | Compositions comprising curons and uses thereof |
US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
US20190046649A1 (en) * | 2017-08-09 | 2019-02-14 | University Of Maryland, Baltimore County | Delivery device and use thereof for loading cell plasma membranes |
EP3668833A1 (en) | 2017-08-16 | 2020-06-24 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
US12065396B2 (en) | 2017-08-17 | 2024-08-20 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
TW201912786A (zh) * | 2017-08-30 | 2019-04-01 | 日本國立研究開發法人國立成育醫療研究中心 | Trec或krec含量的評估方法、該方法所使用之粒子及其用途 |
JP6826014B2 (ja) * | 2017-09-13 | 2021-02-03 | 株式会社東芝 | 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット |
EP3684397A4 (en) | 2017-09-21 | 2021-08-18 | The Broad Institute, Inc. | SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED EDITION OF NUCLEIC ACIDS |
US20200255828A1 (en) | 2017-10-04 | 2020-08-13 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
US12227742B2 (en) | 2017-10-23 | 2025-02-18 | The Broad Institute, Inc. | Nucleic acid modifiers |
US11547614B2 (en) | 2017-10-31 | 2023-01-10 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
BR112020008451A2 (pt) | 2017-11-06 | 2020-12-01 | Nitto Denko Corporation | composto fusogênico, composição, composições farmacêutica e para uso na distribuição de um agente ativo, e, método para prevenir, melhorar ou tratar uma doença ou condição |
EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH |
TW201936201A (zh) | 2017-12-14 | 2019-09-16 | 美商堅固生物科技公司 | 基因之非病毒生產及遞送 |
AU2018392716B2 (en) | 2017-12-20 | 2025-03-13 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
US20230193242A1 (en) | 2017-12-22 | 2023-06-22 | The Broad Institute, Inc. | Cas12b systems, methods, and compositions for targeted dna base editing |
MX2020007945A (es) | 2018-01-29 | 2020-09-24 | Merck Sharp & Dohme | Proteinas f del rsv estabilizadas y usos de las mismas. |
WO2020033601A1 (en) | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Novel cas12b enzymes and systems |
WO2020041380A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
EP3852911B1 (en) | 2018-09-21 | 2025-01-22 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
PL3864163T3 (pl) * | 2018-10-09 | 2024-05-20 | The University Of British Columbia | Kompozycje i układy zawierające pęcherzyki zdolne do transfekcji wolne od rozpuszczalników organicznych i detergentów oraz związane z nimi sposoby postępowania |
WO2020097540A1 (en) | 2018-11-09 | 2020-05-14 | Arbutus Biopharma Corporation | Lipid nanoparticle formulations |
EP3876999A4 (en) | 2018-11-09 | 2022-08-31 | Arbutus Biopharma Corporation | NEGATIVELY CHARGED PEG-LIPID CONJUGATES |
AU2019384557B2 (en) | 2018-11-21 | 2025-07-17 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
EP3908568B1 (en) | 2019-01-11 | 2024-06-26 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
US20220177863A1 (en) | 2019-03-18 | 2022-06-09 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
CA3147875A1 (en) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Recombinase compositions and methods of use |
GB2600859B (en) | 2019-08-14 | 2024-04-03 | Acuitas Therapeutics Inc | Improved lipid nanoparticles for delivery of nucleic acids |
CA3150452A1 (en) | 2019-09-06 | 2021-03-11 | Generation Bio Co. | Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof |
US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
AU2020385378A1 (en) | 2019-11-22 | 2022-04-07 | Generation Bio Co. | Ionizable lipids and nanoparticle compositions thereof |
US20230150926A1 (en) | 2020-03-17 | 2023-05-18 | Genevant Sciences Gmbh | Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells |
EP4127187A1 (en) | 2020-03-24 | 2023-02-08 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics |
AU2021244559A1 (en) | 2020-03-24 | 2022-11-17 | Generation Bio Co. | Non-viral DNA vectors and uses thereof for expressing Gaucher therapeutics |
CN115916163A (zh) | 2020-03-27 | 2023-04-04 | 世代生物公司 | 新型脂质及其纳米颗粒组合物 |
CA3174588A1 (en) | 2020-03-30 | 2021-10-07 | BioNTech SE | Rna compositions targeting claudin-18.2 |
US20230149560A1 (en) | 2020-04-20 | 2023-05-18 | Massachusetts Institute Of Technology | Lipid compositions for delivery of sting agonist compounds and uses thereof |
TW202208629A (zh) | 2020-05-20 | 2022-03-01 | 美商旗艦先鋒創新有限責任公司 | 免疫原性組成物及其用途 |
TW202206097A (zh) | 2020-05-20 | 2022-02-16 | 美商旗艦先鋒創新有限責任公司 | 冠狀病毒抗原組成物及其用途 |
US20230203510A1 (en) | 2020-05-29 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods relating thereto |
US20230203509A1 (en) | 2020-05-29 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods relating thereto |
CN116348149A (zh) | 2020-06-15 | 2023-06-27 | 全国儿童医院研究所 | 用于肌营养不良症的腺相关病毒载体递送 |
KR20230051172A (ko) | 2020-07-16 | 2023-04-17 | 아퀴타스 테라퓨틱스 인크. | 지질 나노 입자에 사용하기 위한 양이온성 지질 |
CA3193746A1 (en) | 2020-09-03 | 2022-03-10 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
US11771652B2 (en) | 2020-11-06 | 2023-10-03 | Sanofi | Lipid nanoparticles for delivering mRNA vaccines |
EP4251170A4 (en) | 2020-11-25 | 2025-03-19 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
US20240148663A1 (en) | 2020-12-18 | 2024-05-09 | Genevant Sciences Gmbh | Peg lipids and lipid nanoparticles |
IL303886A (en) | 2020-12-23 | 2023-08-01 | Flagship Pioneering Inc | Compositions of modified trems and uses thereof |
CN114685778B (zh) * | 2020-12-30 | 2023-10-17 | 苏州艾博生物科技有限公司 | 长循环阳离子脂质体的合成方法 |
US11952461B2 (en) | 2021-03-22 | 2024-04-09 | Sunbio, Inc. | Siloxy polyethylene glycol and derivatives thereof |
WO2022212784A1 (en) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
EP4319803A1 (en) | 2021-04-08 | 2024-02-14 | Vaxthera SAS | Coronavirus vaccine comprising a mosaic protein |
CN115197080A (zh) * | 2021-04-08 | 2022-10-18 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
WO2022232286A1 (en) | 2021-04-27 | 2022-11-03 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
JP2024515788A (ja) | 2021-04-27 | 2024-04-10 | ジェネレーション バイオ カンパニー | 治療抗体を発現する非ウイルスdnaベクター及びその使用 |
CA3173953A1 (en) | 2021-06-11 | 2023-12-10 | Tyson D. BOWEN | Rna polymerase iii promoters and methods of use |
MX2023014855A (es) | 2021-06-14 | 2024-01-31 | Generation Bio Co | Lípidos catiónicos y composiciones de estos. |
WO2023273364A1 (zh) | 2021-06-30 | 2023-01-05 | 天津键凯科技有限公司 | 聚乙二醇脂质及其应用 |
WO2023282296A1 (ja) * | 2021-07-07 | 2023-01-12 | 日油株式会社 | pH応答性脂質誘導体 |
CN114149337B (zh) | 2021-07-07 | 2022-04-29 | 天津键凯科技有限公司 | 一种用于核酸递送的新型可电离脂质及其lnp组合物 |
WO2023001286A1 (zh) | 2021-07-23 | 2023-01-26 | 天津键凯科技有限公司 | 一种多元甘醇修饰的脂质化合物及其制备方法和应用 |
EP4377457A1 (en) | 2021-07-26 | 2024-06-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and uses thereof |
CN115703714B (zh) * | 2021-08-13 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
EP4402121A1 (en) | 2021-09-14 | 2024-07-24 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
CA3232386A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
JP2024534428A (ja) | 2021-09-17 | 2024-09-20 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | 環状ポリリボヌクレオチドを生成するための組成物及び方法 |
JP2024538144A (ja) | 2021-10-18 | 2024-10-18 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | ポリリボヌクレオチドを精製するための組成物及び方法 |
CA3234811A1 (en) | 2021-10-20 | 2023-04-27 | Steven Goldman | Rejuvenation treatment of age-related white matter loss |
EP4426832A1 (en) | 2021-11-03 | 2024-09-11 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Precise genome editing using retrons |
CN118829625A (zh) | 2021-11-16 | 2024-10-22 | 赛欧生物医药股份有限公司 | 新型可电离脂质和脂质纳米颗粒以及它们的使用方法 |
MX2024006134A (es) | 2021-11-22 | 2024-07-29 | Sail Biomedicines Inc | Lipidos ionizables novedosos y nanoparticulas de lipido y metodos para usar los mismos. |
WO2023096990A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovation Vi, Llc | Coronavirus immunogen compositions and their uses |
KR20240122785A (ko) | 2021-11-24 | 2024-08-13 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 면역원성 조성물 및 이의 용도 |
KR20240125931A (ko) | 2021-11-24 | 2024-08-20 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 수두-대상포진 바이러스 면역원 조성물 및 이의 용도 |
JP2024546952A (ja) | 2021-12-16 | 2024-12-26 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤に用いるための脂質 |
WO2023115013A1 (en) | 2021-12-17 | 2023-06-22 | Flagship Pioneering Innovations Vi, Llc | Methods for enrichment of circular rna under denaturing conditions |
WO2023122745A1 (en) | 2021-12-22 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
CA3241026A1 (en) | 2021-12-23 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
AU2023212857A1 (en) | 2022-01-27 | 2024-07-04 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
EP4466250B1 (en) | 2022-01-31 | 2025-03-26 | Genevant Sciences Gmbh | Ionizable cationic lipids for lipid nanoparticles |
AU2023235112A1 (en) | 2022-03-14 | 2024-10-17 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
JP2025510229A (ja) | 2022-03-25 | 2025-04-14 | セイル バイオメディシンズ インコーポレイテッド | 新規のイオン化脂質および脂質ナノ粒子ならびにそれらを使用する方法 |
CN119562762A (zh) | 2022-04-04 | 2025-03-04 | 加利福尼亚大学董事会 | 遗传互补组合物和方法 |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
EP4504252A2 (en) | 2022-04-08 | 2025-02-12 | Flagship Pioneering Innovations VII, LLC | Vaccines and related methods |
WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
EP4522753A2 (en) | 2022-05-13 | 2025-03-19 | Flagship Pioneering Innovations VII, LLC | Double stranded dna compositions and related methods |
JP2025516674A (ja) | 2022-05-13 | 2025-05-30 | ビオンテック エスエー | Hivを標的とするrna組成物 |
IL316504A (en) | 2022-05-25 | 2024-12-01 | BioNTech SE | RNA compositions for the delivery of monkeypox antigens and related methods |
EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
EP4518845A1 (en) | 2022-05-30 | 2025-03-12 | BioNTech SE | Complexes for delivery of nucleic acids |
WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
WO2024030856A2 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
WO2024035952A1 (en) | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
IL318914A (en) | 2022-08-12 | 2025-04-01 | Life Edit Therapeutics Inc | RNA-guided nucleases and active fragments and variants thereof and methods of use |
WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
WO2024049979A2 (en) | 2022-08-31 | 2024-03-07 | Senda Biosciences, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
EP4590331A1 (en) | 2022-09-23 | 2025-07-30 | BioNTech SE | Compositions for delivery of plasmodium csp antigens and related methods |
WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
IL319414A (en) | 2022-09-23 | 2025-05-01 | BioNTech SE | Compositions for delivering antigens at the liver level and related methods |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
IL319682A (en) | 2022-10-06 | 2025-05-01 | BioNTech SE | RNA complexes targeting claudin-18.2 |
AU2023372397A1 (en) | 2022-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
AR131008A1 (es) | 2022-11-08 | 2025-02-05 | Flagship Pioneering Innovations Vi Llc | Composiciones y métodos para producir polirribonucleótidos circulares |
IL320164A (en) * | 2022-11-15 | 2025-06-01 | Evonik Operations Gmbh | Polyoxyalkylene-2,1-dimyristoyl-glycerol compounds where the polyoxyalkylene is poly(ethylene oxide) having C1 to C3-alkyloxymethyl side chains |
WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
WO2024119039A2 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticles and uses thereof |
WO2024119051A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
WO2024129988A1 (en) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for delivery of therapeutic agents to bone |
CN116284743A (zh) * | 2022-12-16 | 2023-06-23 | 辅必成(上海)医药科技有限公司 | 一种甲氧基聚乙二醇2000双十四烷基乙酰胺的制备方法 |
WO2024141955A1 (en) | 2022-12-28 | 2024-07-04 | BioNTech SE | Rna compositions targeting hiv |
WO2024141784A2 (en) | 2022-12-29 | 2024-07-04 | Popvax Private Limited | Broadly protective betacoronavirus vaccines and compositions |
WO2024141786A2 (en) | 2022-12-29 | 2024-07-04 | Popvax Private Limited | Multitarget vaccines and therapeutics |
WO2024151673A2 (en) | 2023-01-09 | 2024-07-18 | President And Fellows Of Harvard College | Recombinant nucleic acid molecules and their use in wound healing |
US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
TW202438673A (zh) | 2023-01-09 | 2024-10-01 | 美商旗艦先鋒創新有限責任(Vii)公司 | 疫苗及相關方法 |
US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
US20240269263A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
US20240293318A1 (en) | 2023-02-13 | 2024-09-05 | Flagship Pioneering Innovations Vii, Llc | Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions |
US20240293582A1 (en) | 2023-02-17 | 2024-09-05 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified cytosine |
WO2024173828A1 (en) | 2023-02-17 | 2024-08-22 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified uracil |
WO2024192420A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising polyribonucleotides and uses thereof |
WO2024192422A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
WO2024216128A1 (en) | 2023-04-12 | 2024-10-17 | Flagship Pioneering Innovations Vi, Llc | Trems for use in correction of missense mutations |
WO2024220653A1 (en) | 2023-04-19 | 2024-10-24 | Gradalis, Inc. | Compositions and methods for modulating sialic acid production and treating hereditary inclusion body myopathy (hibm) |
WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
WO2024228044A1 (en) | 2023-05-03 | 2024-11-07 | BioNTech SE | Optimized csp variants and related methods |
WO2024228150A1 (en) | 2023-05-03 | 2024-11-07 | BioNTech SE | Optimized csp variants and related methods |
US20240401025A1 (en) | 2023-05-03 | 2024-12-05 | Manifold Biotechnologies, Inc. | Methods and compositions for high-throughput protein delivery, screening, and detection |
WO2024233425A2 (en) | 2023-05-08 | 2024-11-14 | Merck Sharp & Dohme Llc | Polynucleotides encoding norovirus vp1 antigens and uses thereof |
WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
WO2025006684A1 (en) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
WO2025024324A1 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
WO2025024335A2 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
WO2025024337A1 (en) | 2023-07-24 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
WO2025024486A2 (en) | 2023-07-25 | 2025-01-30 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
WO2025022367A2 (en) | 2023-07-27 | 2025-01-30 | Life Edit Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2025027089A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thiolipids and uses thereof |
WO2025026545A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thioplipids and uses thereof |
WO2025030097A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
WO2025027576A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
WO2025030154A1 (en) | 2023-08-03 | 2025-02-06 | The Trustees Of The University Of Pennsylvania | Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods |
WO2025027579A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
WO2025052278A1 (en) | 2023-09-05 | 2025-03-13 | Genevant Sciences Gmbh | Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells |
WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
WO2025052180A2 (en) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipids and lipid nanoparticles |
WO2025051994A1 (en) | 2023-09-07 | 2025-03-13 | Coave Therapeutics | Ionizable lipid nanoparticles |
WO2025054556A1 (en) | 2023-09-07 | 2025-03-13 | BioNTech SE | Rna compositions for delivery of mpox antigens and related methods |
WO2025056938A1 (en) | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
WO2025057088A1 (en) | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
WO2025064475A2 (en) | 2023-09-18 | 2025-03-27 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
WO2025072383A1 (en) | 2023-09-25 | 2025-04-03 | The Broad Institute, Inc. | Viral open reading frames, uses thereof, and methods of detecting the same |
WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
WO2025081042A1 (en) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
WO2025083619A1 (en) | 2023-10-18 | 2025-04-24 | Life Edit Therapeutics, Inc. | Rna-guided nucleases and acive fragments and variants thereof and methods of use |
WO2025090427A1 (en) | 2023-10-23 | 2025-05-01 | University Of Rochester | Glial-targeted relief of hyperexcitability in neurodegenerative diseases |
WO2025089649A1 (ko) * | 2023-10-26 | 2025-05-01 | 주식회사 차백신연구소 | 양이온성 리포좀을 포함하는 핵산 전달용 조성물 및 그의 용도 |
WO2025096807A2 (en) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
US20250162981A1 (en) | 2023-11-14 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
WO2025111526A1 (en) | 2023-11-22 | 2025-05-30 | Flagship Pioneering Innovations Vii, Llc | Methods and compositions for treating non-alcoholic fatty liver disease |
CN117883382B (zh) * | 2023-11-27 | 2025-02-14 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途 |
WO2025114520A1 (en) | 2023-12-01 | 2025-06-05 | Coave Therapeutics | Ionizable lipid nanoparticles |
WO2025124711A1 (en) | 2023-12-13 | 2025-06-19 | BioNTech SE | Glycolipid compositions |
WO2025129158A1 (en) | 2023-12-15 | 2025-06-19 | The Broad Institute, Inc. | Engineered arc delivery vesicles and uses thereof |
WO2025134066A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Ionizable lipids |
WO2025134062A2 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Ionizable lipids |
WO2025133951A1 (en) | 2023-12-21 | 2025-06-26 | Genevant Sciences Gmbh | Ionizable lipids suitable for lipid nanoparticles |
WO2025133105A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Compositions and methods |
CN119857055A (zh) * | 2025-03-24 | 2025-04-22 | 广州悦瑞化妆品有限公司 | 一种包裹玻色因的制备方法及其应用 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US716675A (en) * | 1902-06-16 | 1902-12-23 | Pleasant H Hanes Jr | Sliver-can. |
US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
DE3068743D1 (en) * | 1980-01-16 | 1984-08-30 | Weder Hans G | Process and dialysis-installation for the preparation of bilayer-vesicles and their use |
US4598051A (en) * | 1980-03-12 | 1986-07-01 | The Regents Of The University Of California | Liposome conjugates and diagnostic methods therewith |
US4515736A (en) * | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
US5545412A (en) * | 1985-01-07 | 1996-08-13 | Syntex (U.S.A.) Inc. | N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5208036A (en) * | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5320906A (en) * | 1986-12-15 | 1994-06-14 | Vestar, Inc. | Delivery vehicles with amphiphile-associated active ingredient |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
FR2645866B1 (fr) * | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
JPH03126211A (ja) * | 1989-10-12 | 1991-05-29 | Nippon Chemicon Corp | 電解コンデンサ用電解液 |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5225212A (en) * | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5279833A (en) * | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
JP2774417B2 (ja) * | 1991-08-07 | 1998-07-09 | 株式会社ディ・ディ・エス研究所 | ペプチド骨格を有する分枝鎖型糖複合体及び微粒子キャリヤー |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
AU3467193A (en) | 1991-12-17 | 1993-07-19 | Regents Of The University Of California, The | Gene therapy for cystic fibrosis transmembrane conductance regulator activity (CFTR) |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
CA2130264A1 (en) * | 1992-02-19 | 1993-09-02 | Harris Busch | Oligonucleotide modulation of cell growth |
EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
JP2854203B2 (ja) * | 1992-09-03 | 1999-02-03 | 株式会社ディ・ディ・エス研究所 | リポソームの製造法 |
US5578475A (en) | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
US5674908A (en) | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
US6075012A (en) | 1994-02-11 | 2000-06-13 | Life Technologies, Inc. | Reagents for intracellular delivery of macromolecules |
AU696881B2 (en) | 1994-06-22 | 1998-09-24 | Megabios Corporation | Cationic amphiphiles |
FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
US5885613A (en) * | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5627159A (en) | 1994-10-27 | 1997-05-06 | Life Technologies, Inc. | Enhancement of lipid cationic transfections in the presence of serum |
US5811406A (en) | 1995-06-07 | 1998-09-22 | Regents Of The University Of California | Dry powder formulations of polynucleotide complexes |
US6251939B1 (en) | 1995-06-07 | 2001-06-26 | Promega Biosciences, Inc. | Carbamate-based cationic lipids |
JP4338106B2 (ja) | 1995-06-07 | 2009-10-07 | ライフ テクノロジーズ コーポレーション | ペプチド増強カチオン脂質トランスフェクション |
EP1489184A1 (en) * | 1995-06-07 | 2004-12-22 | Inex Pharmaceutical Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US7422902B1 (en) * | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US20030069173A1 (en) | 1998-03-16 | 2003-04-10 | Life Technologies, Inc. | Peptide-enhanced transfections |
JPH11507815A (ja) | 1995-06-07 | 1999-07-13 | ジンタ・インコーポレイテッド | ホスホン酸基本カチオン性脂質 |
US6339173B1 (en) | 1996-07-22 | 2002-01-15 | Promega Biosciences, Inc. | Amide-based cationic lipids |
CA2227373A1 (en) | 1995-07-21 | 1997-02-06 | Promega Biosciences, Inc. | Novel amide-based cationic lipids |
US6330349B1 (en) | 1995-11-30 | 2001-12-11 | Chromavision Medical Systems, Inc. | Automated method for image analysis of residual protein |
US5817856A (en) * | 1995-12-11 | 1998-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
SE520727C2 (sv) * | 1996-03-04 | 2003-08-19 | Ciba Sc Holding Ag | Alkylfenylbisacylfosfinoxid och fotoinitiatorblandningar |
US6284267B1 (en) * | 1996-08-14 | 2001-09-04 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
US5877220A (en) | 1997-03-06 | 1999-03-02 | Genta, Incorporated | Amide-based oligomeric cationic lipids |
US6034135A (en) | 1997-03-06 | 2000-03-07 | Promega Biosciences, Inc. | Dimeric cationic lipids |
US6287591B1 (en) * | 1997-05-14 | 2001-09-11 | Inex Pharmaceuticals Corp. | Charged therapeutic agents encapsulated in lipid particles containing four lipid components |
WO1998051285A2 (en) | 1997-05-15 | 1998-11-19 | Genzyme Corporation | Cationic amphiphile formulations |
AU1360499A (en) | 1997-10-10 | 1999-05-03 | Pieter R. Cullis | Methods for encapsulating nucleic acids in lipid bilayers |
CA2271582A1 (en) | 1998-05-14 | 1999-11-14 | Sean C. Semple | Method for administration of therapeutic agents, including antisense, with repeat dosing |
ATE237312T1 (de) | 1998-07-20 | 2003-05-15 | Protiva Biotherapeutics Inc | In liposomen verkapselte nukleinsäurekomplexe |
US6018175A (en) * | 1998-09-03 | 2000-01-25 | Micron Technology, Inc. | Gapped-plate capacitor |
KR100366320B1 (ko) * | 1998-09-17 | 2002-12-31 | 마츠시타 덴끼 산교 가부시키가이샤 | 부품 공급 방법, 부품 공급 장치, 부품 실장 방법 및 부품실장 장치 |
PT1129064E (pt) | 1998-11-12 | 2008-01-31 | Invitrogen Corp | Reagentes de transfecção |
EP1173600A2 (en) | 1999-04-20 | 2002-01-23 | The University Of British Columbia | Cationic peg-lipids and methods of use |
US6696424B1 (en) * | 1999-05-28 | 2004-02-24 | Vical Incorporated | Cytofectin dimers and methods of use thereof |
CN1193059C (zh) | 1999-07-14 | 2005-03-16 | 阿尔萨公司 | 中性脂质聚合物以及含中性脂质聚合物的脂质体组合物 |
JP4782966B2 (ja) | 2000-01-10 | 2011-09-28 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | 疾患の治療における脂質コンジュゲートの使用 |
US20020086849A1 (en) | 2000-10-27 | 2002-07-04 | Gulilat Gebeyehu | Method for introducing antisense oligonucleotides into eucaryotic cells |
EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
JP2006519262A (ja) * | 2003-02-28 | 2006-08-24 | アルザ・コーポレーシヨン | リポソームにより誘導される補体活性化の減少のためのリポソーム組成物 |
KR101168440B1 (ko) * | 2003-07-16 | 2012-07-27 | 프로티바 바이오쎄라퓨틱스, 인코포레이티드 | 지질 캡슐화된 간섭 rna |
ATE536418T1 (de) * | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
CA2572439A1 (en) * | 2004-07-02 | 2006-01-12 | Protiva Biotherapeutics, Inc. | Immunostimulatory sirna molecules and uses therefor |
WO2006102163A2 (en) | 2005-03-17 | 2006-09-28 | Invitrogen Corporation | Transfection reagents for non-adherent suspension cells |
CN103380113B (zh) | 2010-11-15 | 2018-03-30 | 生命科技公司 | 含胺的转染试剂及其制备和使用方法 |
-
2004
- 2004-09-15 NZ NZ581166A patent/NZ581166A/en not_active IP Right Cessation
- 2004-09-15 JP JP2006526496A patent/JP4842821B2/ja not_active Expired - Lifetime
- 2004-09-15 CN CN2004800336163A patent/CN1882693B/zh not_active Expired - Lifetime
- 2004-09-15 EP EP04761838A patent/EP1664316B1/en not_active Expired - Lifetime
- 2004-09-15 US US10/942,379 patent/US7803397B2/en not_active Expired - Lifetime
- 2004-09-15 NZ NZ592917A patent/NZ592917A/xx not_active IP Right Cessation
- 2004-09-15 CA CA2551022A patent/CA2551022C/en not_active Expired - Lifetime
- 2004-09-15 AU AU2004272646A patent/AU2004272646B2/en not_active Expired
- 2004-09-15 WO PCT/CA2004/001677 patent/WO2005026372A1/en active Application Filing
- 2004-09-15 KR KR1020067006599A patent/KR101164256B1/ko not_active Expired - Fee Related
-
2006
- 2006-03-14 IL IL174315A patent/IL174315A/en active IP Right Grant
-
2010
- 2010-08-06 US US12/852,362 patent/US8936942B2/en not_active Expired - Lifetime
-
2015
- 2015-09-06 IL IL241209A patent/IL241209B/en active IP Right Grant
-
2019
- 2019-01-28 IL IL264517A patent/IL264517B/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150061946A (ko) * | 2013-11-28 | 2015-06-05 | 충남대학교산학협력단 | 효소 절단성 링커 또는 올리고 라이신을 포함하는 폴리에틸렌글리콜-리피드를 이용한 안정화된 플라스미드-지질 입자 |
Also Published As
Publication number | Publication date |
---|---|
NZ581166A (en) | 2011-06-30 |
JP4842821B2 (ja) | 2011-12-21 |
NZ592917A (en) | 2012-12-21 |
EP1664316A1 (en) | 2006-06-07 |
IL241209B (en) | 2019-02-28 |
JP2007505954A (ja) | 2007-03-15 |
AU2004272646B2 (en) | 2011-11-24 |
CA2551022C (en) | 2013-06-04 |
IL264517B (en) | 2021-12-01 |
IL241209A0 (en) | 2015-11-30 |
IL264517A (en) | 2019-02-28 |
IL174315A0 (en) | 2006-08-01 |
US7803397B2 (en) | 2010-09-28 |
CA2551022A1 (en) | 2005-03-24 |
IL174315A (en) | 2015-09-24 |
US20110091525A1 (en) | 2011-04-21 |
CN1882693A (zh) | 2006-12-20 |
EP1664316B1 (en) | 2012-08-29 |
WO2005026372A1 (en) | 2005-03-24 |
AU2004272646A1 (en) | 2005-03-24 |
US20050175682A1 (en) | 2005-08-11 |
US8936942B2 (en) | 2015-01-20 |
EP1664316A4 (en) | 2009-11-25 |
CN1882693B (zh) | 2012-08-15 |
KR101164256B1 (ko) | 2012-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101164256B1 (ko) | 폴리에틸렌글리콜 개질된 지질 화합물 및 그의 용도 | |
AU2005251403B2 (en) | Cationic lipids and methods of use | |
US20060051405A1 (en) | Compositions for the delivery of therapeutic agents and uses thereof | |
US9926560B2 (en) | Lipid encapsulating interfering RNA | |
KR101168440B1 (ko) | 지질 캡슐화된 간섭 rna | |
CN101163796A (zh) | 阳离子脂质及应用方法 | |
HK1103391B (en) | Cationic lipids and methods of use | |
AU2011253734A1 (en) | Cationic lipids and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
A201 | Request for examination | ||
P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
FPAY | Annual fee payment |
Payment date: 20150602 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160630 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170703 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180628 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R14-asn-PN2301 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 10 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 11 |
|
PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20230704 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20230704 |